Drug Approval | November 10, 2024
Granules India’s Unit V facility secures USFDA EIR with NAI status
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
This product will be manufactured at Lupin’s Nagpur facility in India
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
The company uses iPS cells to develop treatments for diseases relating to the kidney
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
Subscribe To Our Newsletter & Stay Updated
